5930

Topic Category: 4114-ASIP Cancer biomarkers

**First Author:** Hellen Joyce Santos Universidade Nove de Julho

Programa pós graduação em medicina Rua Vergueiro, 235 - 2 subsolo São Paulo

Brazil

Phone: 5511974986879 hellensantos1984@gmail.com

First Author is a: Graduate Student

First Author is a member of: Not a Member of a Host EB Society

First Author Degree: MS, MPH, MA. Med, or equivalent

Presentation Preference: Oral

**Sponsor:** KÁTIA de ANGELIS **Sponsor Phone:** 5511992342409 prof.kangelis@yahoo.com.br

Sponsor's Society: Brazilian Society of Physiology (SBFiS) - APS Guest Society Keywords: 1. bladder cancer 2. indoleamine2,3dioxygenase 3. interferon-gamma

## TRANSIENT DOWNREGULATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) IS CRITICAL FOR BLADDER CANCER CELL INVASION

Hellen Joyce Sousa Pereira Santos, Stephanie Vanin Dalmazzo, Luiz Henrique Gomes Matheus, Lucas Alves Pereira, Marina Baptista Floriani...... Humberto Dellê. Programa pós graduação em medicina, Universidade Nove de Julho, São Paulo, Brazil

The most common form of human bladder cancer is non-muscle invasive, however, half of these cases progress to a muscle-invasive, which ultimately leads to metastasis and cancer-specific death. Indoleamine 2,3-dioxygenase (IDO) is an enzyme induced strongly by INF-gamma that has been recognized as an immunomodulatory molecule since it was described in the placenta protecting embryos tissue against maternal immune attack. A growing body of evidence suggests that IDO is expressed in tumors, enabling cancers to evade immune surveillance. Moreover, IDO has presented nonimmunological effects in some tumors. Recently, we demonstrated that IDO expression is suppressed by TGF-beta in bladder cancer cells, an important inductor of cancer invasiveness. Here, we raised the hypothesis that IDO is involved in the bladder cancer cell invasion process. IDO activity, promotes tryptophan breakdown, increasing kyrmrenines in the microenvironment. Amona the IDO eactivated pathways accurates

there is the aryl hydrocarbon receptor, activated by kynurenines, and the GCN2, a pathway sensitive to tryptophan depletion. The analyze the expression of IDO and its pathways AHR and GCN2 during muscle-invasive bladder cancer cell invasion, and to ver gamma-inducted IDO affects cell invasion. T24 cells underwent starvation for 24h and then were seeded in Matrigel/transwell sys hours, in order to separate invasive cells (IC) from non-invasive cells (NIC). The IC cells, which migrated to transwell, were trypsiniz RNA was extracted. Concomitantly, Matrigel-retained cells were isolated as NIC, and total RNA was extracted. In the second phas experiment was performed, however, IC and NIC cells were collected and subcultivated in RPMI 1640 10% FCS for 18 days, Finally, phase, INF-gamma-treated T24 cells and non-INF-gamma-treated T24 cells were seemed in the Matrigel/transwell system to migration rate after 24h. Real-time PCR for IDO, CYP1A1 (AHR activation marker), and CHOP (GCN2 activation marker) was carried expression was lower in IC versus NIC (relative expression 1.02 ± 0.27 vs. 6.15 ± 1.60, p<0.05). In addition, expression of CYP1A1 also decreased in IC (relative expression of CYP1A1 of 1.00  $\pm$  0.12 in IC vs. 3.15  $\pm$  0.46 in NIC, p<0.05; and relative expression of  $1.06 \pm 0.23$  in IC vs.  $0.36 \pm 0.06$  in NIC, p<0.05). The culture of IC and NIC over a long time (18 days) showed that the differ expression of IDO, CYP1A1 and CHOP previously found disappeared. The treatment with INF-gamma significantly increased the ex IDO in total T24 cells (60X), demonstrating T24 cells responsiveness to INF-gamma. The Matrigel/transwell analysis showed that the with INF-gamma significantly reduced the invasion rate when compared to non-treated cells (70.3 ± 92.5 vs. 1925.7 ± 2077.6 cel. There is a loss of IDO expression and consequently loss of AHR and GCN2 activation during T24 cell invasion. The induction of IDO gamma diminished T24 cells invasiveness. These results point to a new mechanism of IDO in the bladder tumorigenesis, reinforced to the control of the bladder tumorigenesis and the control of the bladder tumorigenesis and the control of the bladder tumorigenesis. therapeutic target in bladder cancer.

Support or Funding Information

FUNDAÇÃO DE AMPARO A PESQUISA DO ESTADO DE SÃO PAULO PROJETO 2016/04105-0 CAPES

paumaya. aim was to ify if INFtem for 24 ed and total e, the same in the third nalyze the d-out. IDO and CHOP f CHOP of ence in the oression of stimulation s. p<0.05). with INF-

ing it as a